Form 4: PAVmed Director Sparks Boosts Stake with Restricted Stock

PAVmed Inc. Director Ronald M. Sparks received a grant of 150,000 restricted common shares, increasing his beneficial ownership to 215,000 shares, under the company's long-term incentive plan.

Summary

• Ronald M. Sparks, a Director of PAVmed Inc., was granted 150,000 shares of common stock.
• The transaction date for this grant is September 30, 2025.
• These shares are restricted stock granted under the issuer's Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan.
• The restricted stock has a single vesting date of May 20, 2028.
• The shares are subject to forfeiture if the requisite service period is not completed.
• Following this transaction, Ronald M. Sparks beneficially owns 215,000 shares of common stock.

Sentiment

Score: 7

Explanation: The grant of restricted stock to a director is generally a positive signal as it aligns management's interests with shareholders for long-term value creation. However, it is a compensation event rather than an open market purchase, which would typically carry a stronger positive sentiment.

Positives

• The grant of restricted stock aligns the director's interests with those of shareholders, incentivizing long-term performance.
• The transaction is part of a pre-planned long-term incentive equity plan, indicating structured compensation.

Risks

• The restricted stock is subject to forfeiture if the requisite service period is not completed, posing a risk to the director's ultimate ownership of these shares.

Future Outlook

The restricted stock grant indicates a future vesting event on May 20, 2028, contingent on the director completing the requisite service period, aligning future performance with compensation.

Management Comments

• The grant represents restricted stock under the issuer's Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan.

Industry Context

The grant of restricted stock to a director is a common practice in the biotechnology and medical device industry, similar to other sectors, used to attract, retain, and incentivize key management and board members by aligning their long-term interests with company performance and shareholder value.

Comparison to Industry Standards

• Restricted stock grants are a standard component of executive and director compensation packages across various industries, including healthcare and technology, often tied to long-term incentive plans to promote retention and performance.
• The vesting schedule, with a single vesting date in 2028, is typical for long-term incentive awards, comparable to practices at companies like Medtronic or Boston Scientific, which use multi-year vesting to ensure sustained commitment.

Corporate Governance

Related Party Transactions

• The grant of 150,000 shares of restricted common stock to Ronald M. Sparks, a Director of PAVmed Inc., constitutes a related party transaction as it involves compensation from the company to a member of its board.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with long-term shareholder value creation, potentially leading to more focused strategic decisions.
• Director (Ronald M. Sparks): Receives equity compensation, subject to future vesting and service requirements, incentivizing continued service and performance.

Next Steps

• The restricted stock will vest on May 20, 2028, provided the requisite service period is completed.

Key Dates

Keywords

PAVmed, PAVM, Form 4, Insider Transaction, Restricted Stock, Director Compensation, Equity Plan, Beneficial Ownership